Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Clinical trial NCT05432388 · COMPLETED

Trial details

NCT number: NCT05432388
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Allergy, Peanut

Start date: 2022-10-12
Primary completion: 2025-03-11
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.